Murepavadin

Drug Profile

Murepavadin

Alternative Names: POL 7080; RG 7929

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Polyphor
  • Class Antibacterials; Cyclic peptides
  • Mechanism of Action Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pseudomonal infections
  • No development reported Gram-negative infections

Most Recent Events

  • 12 Nov 2017 Preclinical trials in Pseudomonal infections in Switzerland (Inhalation)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Europe (IV, Infusion)
  • 12 Oct 2017 Polyphor plans a pivotal trial in Pseudomonal infections (nosocomial pneumonia) in the first months of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top